ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paradigm Biopharmaceuticals Stock (ASX:PAR) 30 days 90 days 365 days Advanced Chart Get PAR alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket CapitalizationA$196.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia. Read More Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PAR Stock News Headlines‘The Recruit’ & ‘Atypical’ Star Fivel Stewart Signs With ParadigmJuly 18 at 5:40 AM | msn.comParadigm Biopharmaceuticals Issues 7 Million Convertible NotesJuly 7, 2025 | tipranks.comTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.July 18 at 2:00 AM | Porter & Company (Ad)Paradigm Biopharmaceuticals Limited (PBIGF) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.com‘After Typhoon’ Star & UFC Champion Zhang Weili Signs With ParadigmJuly 2, 2025 | msn.comTony Award Nominee John Douglas Thompson Signs With ParadigmJuly 1, 2025 | msn.comParadigm unlocks $40M loan – and sees a 75cps price not far awayJune 30, 2025 | msn.comParadigm Biopharmaceuticals Ltd Stock Price HistoryJune 26, 2025 | investing.comSee More Headlines PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryComputer Hardware Current SymbolASX:PAR CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,480Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$58.65 million Net Margins-89,138.58% Pretax MarginN/A Return on Equity-203.64% Return on Assets-86.16% Debt Debt-to-Equity Ratio1.01 Current Ratio7.22 Quick Ratio5.93 Sales & Book Value Annual SalesA$79.22 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares350,360,000Free FloatN/AMarket CapA$196.66 million OptionableNot Optionable Beta0.94 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (ASX:PAR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PAR Stock Alerts